In conclusion, given the widespread impact of CDK12/13 on gene expression at different layers of regulation and the high anti-tumoral efficacy of CDK12/13 inhibitors alone or in combination with other chemotherapeutic agents, it is hoped in the near future an increased number of clinical trials especially for brain tumour patients for whom very few therapeutic options are currently available. Here, CDK12 is linked to brain neoplasm.